Articles tagged with Osteosarcoma
Child cancer groups are urging a concerted effort to tackle pediatric sarcomas, a rare and aggressive form of childhood cancer. The groups propose three key priorities to improve collaboration, data sharing, and clinical infrastructure to translate discoveries into effective treatments.
Scientists at St. Jude Children's Research Hospital discovered removing Regnase-1 from engineered immune cells enhances CAR T-cell therapy's ability to control osteosarcoma growth and prevent metastasis. The modified cells also alter their tumor microenvironment, activating immune cells and reducing immunosuppressive signals.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
A new study published in Genes & Cancer identifies activated beta-catenin as a key driver of aggressive pediatric osteosarcoma progression. The researchers found that cells expressing active beta-catenin exhibited enhanced invasive capacity and cancer-associated traits, suggesting a potential therapeutic target for this aggressive cancer.
This study reveals Yanghe Decoction's anti-tumor effects on osteosarcoma cells by modulating the PI3K/AKT and p38 MAPK pathways, inducing ROS-mediated mitochondrial dysfunction. YHD also inhibits tumor growth and metastasis in orthotopic OS mouse models.
Scientists at Georgetown University have found that ezrin's closed form binds to RNA, influencing gene translation and supporting cancer cell growth. The discovery may lead to new treatments for osteosarcoma and other ezrin-dependent cancers.
Researchers have developed dual-function biomaterials that can suppress tumors and regenerate bone, offering a promising strategy to address the challenges of postoperative osteosarcoma. The materials are designed to enhance antitumor efficacy while minimizing systemic toxicity, and also provide structural support for bone regeneration.
Researchers identified a previously unknown gene, SMARCAL1, that increases the risk of developing osteosarcoma in children and young adults. The study found that approximately 2.6% of children with osteosarcoma carry inherited mutations in SMARCAL1, which may weaken DNA repair and promote tumor growth.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
Researchers identify three primary UPR pathways and their downstream cascades, which play a crucial role in the differentiation of osteoblasts and osteoclasts. Targeting these pathways with emerging drugs may alleviate bone-related events and kill tumors localized in bones.
Researchers successfully treat mouse tumor with radioactive carbon ion beam, achieving complete control without major neurological side effects. The BARB project advances image-guided particle therapy using exotic beams, showing feasibility and effectiveness.
Research reveals Nrf2's role in chemoradiotherapy resistance and multi-drug resistance in osteosarcoma cells. Elevated Nrf2 expression correlates with reduced survival rates.
Osteosarcoma cells often have extra copies of the SETDB1 gene, making the cancer more aggressive and harder to treat. Blocking SETDB1 may help the immune system recognize and attack osteosarcoma cells, offering a promising new way to treat this type of bone cancer.
A new study identifies loss-translocation-amplification chromothripsis as a key mechanism driving osteosarcoma tumour development and evolution. This discovery has significant implications for treatment options and patient outcomes, highlighting the importance of investing in studies exploring cancer mechanisms.
Researchers have identified three distinct subtypes of osteosarcoma using advanced mathematical modeling and machine learning. This breakthrough could transform clinical trials and patient care by enabling targeted treatment personalized to individual cancer subtypes.
Ewing sarcoma, a rare childhood cancer, is made more aggressive by the absence of STAG2 protein. This discovery provides potential biomarkers and therapeutic targets for treatment.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
Researchers at Aston University have created a potential treatment for bone cancer using gallium-doped bioactive glasses, which has shown a 99% success rate in killing osteosarcoma cells. The therapy also promotes early stages of bone formation and regenerates diseased bones.
Researchers identify key genes involved in osteoblast differentiation, finding positive correlations between WNT10B and these genes, and inverse correlations with WNT5B. The study hypothesizes that the use of WNT activators or inhibitors depends on whether canonical or non-canonical pathways are activated.
Scientists at St. Jude Children's Research Hospital identified two chemokines, CXCL8 and CXCL16, expressed by osteosarcoma that improved CAR T-cell homing. Modified cells expressing these chemokine receptors showed enhanced infiltration into tumors, leading to prolonged survival in a model of metastatic disease.
A new Europe-wide clinical framework aims to collect high-quality biological samples from patients, enabling researchers and clinicians to understand the genetic, biological, and other factors involved in childhood bone cancer. This will guide the development of tailored treatments for each patient's cancer type.
A new type of immunotherapy has been developed to treat bone cancer osteosarcoma, with promising preclinical results in mice. The treatment uses gamma-delta T cells, which are less well-known immune cells that can be engineered to target tumours.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
Researchers developed an AI model to detect viable tumor cells in osteosarcoma patients, improving prognosis predictions. The model showed comparable detection performance to pathologists and reduced inter-assessor variability, enabling timely assessment.
Researchers found that secreted frizzled-related protein 2 (SFRP2) is abundantly expressed in pancreatic cancer, with higher levels linked to poorer outcomes. Blocking SFRP2 may affect tumor growth, angiogenesis, and the immune system, making it a potential therapeutic target.
Researchers at Johns Hopkins Medicine created a machine learning model to calculate percent necrosis in osteosarcoma patients after chemotherapy. The model achieved an 85% positive correlation with musculoskeletal pathologist results, increasing accuracy to 99% when one outlier was removed. This could help provide patients with earlier...
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Researchers at Brigham and Women's Hospital have identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma. MicroRNA nanoparticles delivered locally using a hydrogel suppressed osteosarcoma growth while decreasing bone damage.
Researchers have identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma, a bone cancer primarily affecting children and adolescents. The novel combination of gene therapy and chemotherapy may improve treatment outcomes and aid in the repair of damaged bones during chemotherapy.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Researchers develop unsupervised machine learning algorithm to classify osteosarcoma at diagnosis based on gene expression modules. This approach enables personalized treatment strategies for osteosarcoma patients.
A study found that Spp24 inhibits osteosarcoma tumor cell proliferation, invasiveness, and promotes apoptosis. It achieves this by neutralizing bone morphogenetic protein 2.
A new study found that long-term voluntary wheel running improved skeletal muscle and bone parameters in female mice, but the effects varied depending on body weight. High body weight was more beneficial for muscle and bone health with aging, especially when combined with exercise.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Researchers at MUSC discovered a new target and immune mechanism for treating aggressive metastatic pediatric osteosarcoma. The SFRP2-PD-1 combination therapy effectively blocked cancer cell growth, providing an additive beneficial effect in preclinical models.
Researchers at the University of Texas MD Anderson Cancer Center have identified a new surface protein, MT1-MMP, as a promising therapeutic target for osteosarcoma. The protein is highly expressed on the surface of osteosarcoma cells but not in normal human tissues, making it an attractive target for antibody-drug conjugate therapy.
A study by University of Bristol Veterinary School has identified 27 breeds at higher risk of osteosarcoma due to their body size and shape. The research used data from over 1,700 confirmed cases, finding that dogs with shorter skulls and legs have lower osteosarcoma risk.
A study published in the Journal of Dental Research found no association between community water fluoridation and an increased risk of osteosarcoma. The research, which analyzed data from over 500 patients, suggests that living in a fluoridated area is not a risk factor for osteosarcoma.
A recent NIH study has found that a significant proportion of children with osteosarcoma carry genetic variants associated with increased cancer risk. The researchers identified harmful or likely harmful variants in over a quarter of patients, highlighting the importance of genetic testing and screening for family members.
A new study has identified multiple factors contributing to osteosarcoma's poor responses to immunotherapy, including low immune cell infiltration and suppressed immune-stimulating neoantigens. The research provides insights into strategies for improving outcomes with immunotherapy in rare cancer types.
Researchers found that targeting IL23, an immune molecule central to osteosarcoma development, can successfully shrink tumours in mice. The study provides hope for new treatments and repurposed therapy for this rare form of cancer.
Dr. Alex Huang is awarded a three-year, $1.35 million grant to develop new ways to treat osteosarcoma, a rare cancer that begins in the bone. His research team aims to create immune-based clinical trials to improve treatment outcomes for pediatric and young adult patients.
A novel immunotherapy treatment combining a molecule expressed by cancer cells with Listeria monocytogenes has shown promising results in clinical trials for dogs with osteosarcoma. The vaccine supplements standard treatment and has been shown to improve survival times, with median survival of 956 days compared to 423 days.
A vaccine combining a cancer molecule with Listeria bacteria aims to improve longevity and quality of life for dogs with osteosarcoma. Researchers will conduct clinical trials to evaluate the vaccine's effectiveness in 80 dogs.
Dr. Alex Huang's research aims to understand how macrophages support osteosarcoma growth in lung tissues and develop effective therapeutic options for pulmonary osteosarcoma metastasis.
Researchers successfully identified pulmonary metastases in a patient with osteosarcoma, making it easier to locate tumors for resection. The technique utilizes targeted fluorescence and binds to specific molecular markers, allowing for the detection of small or hard-to-locate nodules.
Researchers at Hong Kong Baptist University have developed a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma. The aptamer-functionalised lipopolymer delivery system successfully delivered CRISPR/Cas9 to tumor cells, inhibiting malignancy and angiogenesis.
A preclinical study published in PNAS found that BMTP-11 targets high-risk osteosarcoma and shows anti-tumor activity. The treatment has the potential to reduce cumulative side effects associated with current treatments, which often cause health problems and organ damage.
A genetic study has identified a subset of osteosarcoma patients who may respond to IGF1R inhibitors based on their genetic profile. The study found that 10% of patients with a specific mutation in growth factor signalling genes could benefit from existing drugs.
A new therapeutic pathway has been discovered to keep cancer cells dormant, offering hope for treating osteosarcoma and potentially other cancers. Researchers found three microRNAs that can inhibit the growth of cancer cells, allowing them to remain asymptomatic and manageable.
A new study from the University of Minnesota Academic Health Center found DNA imprinting defects in children with osteosarcoma and their parents. The researchers suggest that these defects may be a cause of the disease's pathobiology, and could lead to targeted treatments using DNA- and chromatin-modifying drugs.
Scientists at Princess Margaret Cancer Centre discovered that blocking the master regulator of bone renewal, RANKL, stops osteosarcoma. The findings provide a strong rationale for using this drug to develop targeted therapy for patients.
Ezrin regulates osteosarcoma's spread by acting as an air traffic controller, coordinating multiple functions within cancer cells and allowing them to survive stress conditions. Researchers have developed molecules that block ezrin's function, preventing osteosarcoma spread in mouse models.
Researchers at the University of Minnesota Academic Health Center have developed a new genetic mouse model that reveals genes and pathways driving osteosarcoma. The model identifies SEMA4D and SEMA6D as key proteins to target in osteosarcoma treatment.
A study published in Cell Reports found that 90% of osteosarcomas, the most common childhood bone tumor, have mutations in the TP53 gene. This alteration helps explain why standard doses of radiation therapy are largely ineffective against these tumors.
A recent study found that in K9 osteosarcoma samples, NOTCH signaling was elevated overall but aspects of Notch signaling were noticeably deactivated in the worst cancers. The researchers also discovered that HES1 protein expression was lower in aggressive tumors, contradicting previous expectations.
A novel protein governing metastasis and chemoresistance in pediatric osteosarcoma has been discovered using K9 osteosarcoma samples. The IGF2BP1 protein's overexpression is linked to aggressive disease progression, offering a potential target for treatment.
Researchers at Nationwide Children's Hospital have created a new drug to target osteosarcoma, the most common bone tumor in children, using a modified version of Celebrex. The drug, 8A, selectively inhibits the STAT3 pathway, which is crucial for tumor formation and cancer progression.